The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/100 - 1/500. Detects a band of approximately 55 kDa (predicted molecular weight: 65 kDa).
Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain.
Heart and skeletal muscles. Increased expression in the apical tissue compared to the interventricular septal tissue.
Involvement in disease
Defects in MYLK2 are a cause of familial hypertrophic cardiomyopathy (CMH) [MIM:192600]; also designated FHC or HCM. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. Contains 1 protein kinase domain.
Cytoplasm. Colocalizes with phosphorylated myosin light chain (RLCP) at filaments of the myofibrils.
ab71827 at 1/50 dilution, staining MYLK2 in human hepatocarcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue, followed by peroxidase-conjugated secondary antibody and AEC staining.